ResultsIQ › Latest results › IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited Q2 FY27 earnings call summary
NSE: IOLCP · BSE: 524164
Earnings call of 2 Nov 2026, summarised by AI from the filing.
Non-ibuprofen portfolio grew about 70% Y-o-Y in Q2 and is now 45% of pharmaceutical revenue versus 38%.
Key takeaways
- Non-ibuprofen APIs Non-ibuprofen portfolio grew about 70% Y-o-Y in Q2 and is now 45% of pharmaceutical revenue versus 38%.
IOL Chemicals and Pharmaceuticals Limited Q2 FY27 results
As filed: Revenue ₹795 cr (+40% year on year), EBITDA ₹109 cr (+95% year on year), PAT ₹65.1 cr (+117% year on year), EBITDA margin 13.8% (+390 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹756 cr (+37% year on year), EBITDA ₹103 cr (+64% year on year), PAT ₹64.4 cr (+89% year on year), EBITDA margin 13.7% (+227 bps). Score 98 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 227 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Profit rose ₹30.4 cr on a year ago, more than the ₹4.0 cr it added the year before. Share price after the results: +24.7% in 30 days (Nifty 500: −3.2%).
- Q4 FY26: Revenue ₹619 cr (+17% year on year), EBITDA ₹92.5 cr (+47% year on year), PAT ₹53.2 cr (+71% year on year), EBITDA margin 14.9% (+300 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 300 bps year on year. Profit rose ₹22.2 cr on a year ago, more than the ₹3.0 cr it added the year before. Share price after the results: +18.2% in 30 days (Nifty 500: +2.8%).
- Q3 FY26: Revenue ₹580 cr (+11% year on year), EBITDA ₹57.3 cr (+22% year on year), PAT ₹20.6 cr (+38% year on year), EBITDA margin 9.9% (+88 bps). Score 72 of 100, Above trend. Revenue and profit before exceptional items growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 88 bps year on year. Profit fell 3% from last quarter. Share price after the results: −15.0% in 30 days (Nifty 500: −9.9%).
- Q2 FY26: Revenue ₹568 cr (+8% year on year), EBITDA ₹56.0 cr (+33% year on year), PAT ₹30.0 cr (+58% year on year), EBITDA margin 9.9% (+187 bps). Score 77 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 187 bps year on year. Profit fell 12% from last quarter. Share price after the results: −5.4% in 30 days (Nifty 500: −0.6%).
- Q1 FY26: Revenue ₹552 cr (+10% year on year), EBITDA ₹63.0 cr (+21% year on year), PAT ₹34.0 cr (+13% year on year), EBITDA margin 11.4% (+105 bps). Score 71 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 105 bps year on year. Share price after the results: +1.9% in 29 days (Nifty 500: +0.7%).
- Q4 FY25: Revenue ₹528 cr (+5% year on year), EBITDA ₹63.0 cr (+31% year on year), PAT ₹31.0 cr (+11% year on year), EBITDA margin 11.9% (+241 bps). Score 71 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 241 bps year on year. Share price after the results: +10.6% in 28 days (Nifty 500: +0.2%).
- Q3 FY25: Revenue ₹523 cr (+1% year on year), EBITDA ₹47.0 cr (+7% year on year), PAT ₹21.0 cr (−9% year on year), EBITDA margin 9.0% (+53 bps). Score 55 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin rose 53 bps year on year.
Past price moves after results do not indicate future moves. Not a recommendation.
IOL Chemicals and Pharmaceuticals Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (2 Nov 2026), Results deck (31 Oct 2026)
- Q1 FY27: Earnings call (13 Aug 2026), Results deck (12 Aug 2026), Results press release (10 Aug 2026)
- Q4 FY26: Earnings call (22 May 2026), Results deck (21 May 2026), Results press release (20 May 2026)
- Q3 FY26: Earnings call (12 Feb 2026), Results deck (12 Feb 2026), Results press release (11 Feb 2026)
- Q2 FY26: Earnings call (13 Nov 2025), Results deck (12 Nov 2025), Results press release (11 Nov 2025)
- Q1 FY26: Earnings call (8 Aug 2025), Results deck (7 Aug 2025), Results press release (7 Aug 2025)
- Q4 FY25: Earnings call (20 May 2025), Results deck (19 May 2025), Results press release (16 May 2025)
- Other events: Special call (11 Sep 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.